Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Thalidomide usage in Wales: the need to follow guidelines

Chave, T. A., Finlay, Andrew Yule and Knight, A. G. 2001. Thalidomide usage in Wales: the need to follow guidelines. British Journal of Dermatology 144 (2) , pp. 310-315. 10.1046/j.1365-2133.2001.04020.x

Full text not available from this repository.

Abstract

BACKGROUND: Thalidomide is a potentially useful drug for several dermatological disorders. OBJECTIVES: To assess prescribing and monitoring practices for this drug in Wales. METHODS: A questionnaire was completed by 17 of 19 consultant dermatologists concerning thalidomide usage in Wales (population 2.93 million). RESULTS: Eleven of the 17 respondents had used thalidomide in 40 patients. Only two consultants gave information leaflets and only five obtained written consent. Four obtained baseline nerve conduction studies and nine obtained these during therapy. Of seven women of child-bearing age currently taking thalidomide, none had had baseline pregnancy tests. CONCLUSIONS: We describe variability in prescribing practices for thalidomide. Published guidelines are reviewed and suggestions made concerning consent forms, pregnancy testing, nerve conduction studies and patient information.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
R Medicine > RL Dermatology
R Medicine > RZ Other systems of medicine
Uncontrolled Keywords: Guidelines; peripheral neuropathy; teratogenicity; thalidomide. Substances. Dermatologic Agents,Teratogens,Thalidomide
Publisher: Wiley-Blackwell
ISSN: 0007-0963
Last Modified: 04 Jun 2017 07:47
URI: http://orca-mwe.cf.ac.uk/id/eprint/67884

Citation Data

Cited 10 times in Google Scholar. View in Google Scholar

Cited 12 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item